Research Papers:

Tunicamycin enhances the antitumor activity of trastuzumab on breast cancer in vitro and in vivo

Xiqian Han _, Xiaobing Zhang, Hui Li, Shengshi Huang, Shu Zhang, Fengshan Wang and Yikang Shi

PDF  |  HTML  |  How to cite

Oncotarget. 2015; 6:38912-38925. https://doi.org/10.18632/oncotarget.5334

Metrics: PDF 2495 views  |   HTML 3901 views  |   ?  


Xiqian Han1,*, Xiaobing Zhang1,*, Hui Li1,*, Shengshi Huang1, Shu Zhang1, Fengshan Wang1, Yikang Shi1

1National Glycoengineering Research Center, School of Pharmaceutical Science, Shandong University, Jinan, China

*These authors have contributed equally to this work

Correspondence to:

Yikang Shi, e-mail: [email protected]

Keywords: trastuzumab, tunicamycin, breast cancer

Received: May 25, 2015     Accepted: August 26, 2015     Published: October 12, 2015


Trastuzumab, a humanized monoclonal antibody targeting HER2, has demonstrated clinical benefits for women with HER2-positive breast cancer; however, trastuzumab resistance remains the biggest clinical challenge. In this study, results showed that tunicamycin, an inhibitor of N-glycosylation, synergistically enhanced the antitumor activity of trastuzumab against HER2-overexpressing breast cancer cells through induction of cell cycle arrest and apoptosis. Combined treatment of tunicamycin with trastuzumab dramatically decreased the expression of EGFR family and its down signaling pathway in SKBR3 and MCF-7/HER2 cells. Tunicamycin dose-dependently inhibited tumor growth in both of SKBR3 xenografts and MCF-7/HER2 xenografts. Optimal tunicamycin without inducing ER stress in liver tissue significantly increased the antitumor effect of trastuzumab in MCF-7/HER2 xenografts. Combinations of trastuzumab with N-glycosylation inhibitors tunicamycin may be a promising approach for improving clinical efficacy of trastuzumab.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 5334